Boston Scientific Corporation has been the subject of 272 FDA enforcement/approval records tracked by Argus HQ, compared to 3 for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon.
Boston Scientific Corporation: 0 warning letters, 272 recalls, 0 approval records, 0 Form 483s.
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: 0 warning letters, 3 recalls, 0 approval records, 0 Form 483s.
Side by side
Boston Scientific Corporation — Warning letters0
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Warning letters0
Boston Scientific Corporation — Recalls272
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Recalls3
Boston Scientific Corporation — Approval records0
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Approval records0
Boston Scientific Corporation — Form 483s0
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Form 483s0
Timeline
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Most recent FDA action: February 1, 2023
Full history →Cite this comparison
Pre-formatted for a story, footnote, or reference list:
"Boston Scientific Corporation vs Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: FDA Enforcement Comparison." Argus HQ, accessed July 17, 2026. https://argushq.ai/compare/boston-scientific-corporation-vs-glaxosmithkline-consumer-healthcare-holdings-dba-haleon
Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗